⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNYSE

BMY

Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

61.48USD

-1.5200 (-2.41%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on BMY.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$1.25▼$1.6118
Next quarter$1.62▲$1.5454
Current year$6.57▲$6.3418
Next year$6.61▲$6.284

Recent quarters

Beat in 4 of the last 4

QuarterEstimateActualSurprise
2026-06-30$1.6$2.04+0.44 (+27.7%)
2026-03-31$1.42$1.58+0.16 (+11.2%)
2025-12-31$1.2$1.26+0.06 (+4.6%)
2025-09-30$1.52$1.63+0.11 (+7.6%)

Wall Street coverage

303 ratings from 39 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
Wells FargoMaintainedEqual-Weight$65 $60Oct 13, 2026
Cantor FitzgeraldMaintainedNeutral$59 $53Oct 8, 2026
Morgan StanleyMaintainedUnderweight$40 $41Oct 7, 2026
Leerink PartnersDowngraded from OutperformMarket Perform$73 $59Oct 5, 2026
Piper SandlerReiteratedOverweight$75 $82Sep 16, 2026
HSBCMaintainedHold$60 $65Sep 10, 2026
Argus ResearchUpgraded from HoldBuy$75Aug 5, 2026
CitigroupMaintainedNeutral$66 $70Aug 3, 2026
RBC CapitalMaintainedSector Perform$60 $64Jul 31, 2026
JP MorganMaintainedOverweight$67 $73Jul 31, 2026
Cantor FitzgeraldMaintainedNeutral$54 $59Jul 31, 2026
Wells FargoMaintainedEqual-Weight$60 $65Jul 31, 2026
GuggenheimMaintainedBuy$72 $75Jul 31, 2026
Truist SecuritiesReiteratedBuy$65 $70Jul 31, 2026
B of A SecuritiesMaintainedBuy$67 $66Jul 10, 2026
Cantor FitzgeraldReiteratedNeutral$54Jul 6, 2026
B of A SecuritiesMaintainedBuy$68 $67Apr 9, 2026
GuggenheimReiteratedBuy$72Apr 8, 2026
Cantor FitzgeraldMaintainedNeutral$45 $54Apr 8, 2026
HSBCMaintainedHold$53 $60Mar 17, 2026
RBC CapitalInitiatedSector Perform$60Feb 25, 2026
Piper SandlerMaintainedOverweight$66 $75Feb 23, 2026
BarclaysInitiatedOverweight$75Feb 20, 2026
CitigroupMaintainedNeutral$60 $64Feb 6, 2026
Wells FargoMaintainedEqual-Weight$55 $60Feb 6, 2026

Insider transactions

69 filings from 24 insiders · 7 buy / 2 sell over 6m

Officers and directors of BMY, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
Gallman CariOfficer, EVP, General CounselExerciseRestricted Stock Units4.6k——Oct 2, 2026
Gallman CariOfficer, EVP, General CounselTax2.3k$61.15$143kOct 2, 2026
Gallman CariOfficer, EVP, General CounselExercise4.6k——Oct 2, 2026
Samuels Theodore R. IIDirectorGrantDeferred Share Units821.314$62.40$51kSep 30, 2026
McMullen Michael R.DirectorGrantDeferred Share Units560.897$62.40$35kSep 30, 2026
Rice Derica WDirectorGrantDeferred Share Units620.994$62.40$39kSep 30, 2026
Arduini Peter JDirectorGrantDeferred Share Units560.897$62.40$35kSep 30, 2026
YALE PHYLLIS RDirectorGrantDeferred Share Units560.897$62.40$35kSep 30, 2026
Massacesi CristianOfficer, EVP,Chief Med Offr,Head of DevSell6.2k$64.57$403kSep 9, 2026
Short Bartie WendyOfficer, EVP, Corporate AffairsExerciseRestricted Stock Units1.2k——Sep 1, 2026
Short Bartie WendyOfficer, EVP, Corporate AffairsTax633$66.92$42kSep 1, 2026
Short Bartie WendyOfficer, EVP, Corporate AffairsExercise1.2k$66.92$83kSep 1, 2026
HOLZER PHIL MOfficerSell500$67.50$34kAug 25, 2026
GALLMAN CARIGeneral CounselOther1.1k——Jul 31, 2026
MASSACESI CRISTIANOfficerOther51.2k——Jul 31, 2026
HALLER JULIA ADirectorExercise20.5k$53.76$1.10MJun 15, 2026
SHORT BARTIE WENDYOfficerOther8.0k——Jun 3, 2026
LENKOWSKY ADAMOfficerOther1.4k——May 1, 2026
SHANAHAN KARINOfficerOther3.3k——Apr 1, 2026
ELKINS DAVID VINCENTChief Financial OfficerSell30.0k$61.60$1.85MApr 1, 2026

Analyst Notes

Sign in to write

No analyst notes on BMY yet.

Analyst Ratings

24 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current461710Hold2.54
1 mo ago371710Hold2.57
2 mo ago371710Hold2.57
3 mo ago361810Hold2.61
Price target$65.42$41.00 – $82.00
+6.4% to target

Top voices on BMY

Members whose judged calls on BMY have played out most reliably.

No settled calls on BMY yet. Nobody has filed a call with a deadline on it.

A member is listed once they have three judged calls on a name.

Sign in to make a call

A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.

A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.

A member’s prediction, judged on price history · not investment advice